MA47657A1 - Compositions and methods for the internalization of enzymes - Google Patents
Compositions and methods for the internalization of enzymesInfo
- Publication number
- MA47657A1 MA47657A1 MA47657A MA47657A MA47657A1 MA 47657 A1 MA47657 A1 MA 47657A1 MA 47657 A MA47657 A MA 47657A MA 47657 A MA47657 A MA 47657A MA 47657 A1 MA47657 A1 MA 47657A1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- compositions
- internalization
- enzymes
- lysosome
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title abstract 3
- 108090000790 Enzymes Proteins 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 210000003712 lysosome Anatomy 0.000 abstract 2
- 230000001868 lysosomic effect Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 230000002132 lysosomal effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des compositions et des méthodes de traitement de maladies caractérisées par une déficience enzymatique. Des protéines thérapeutiques multidomaines contenant un domaine de liaison à l'effecteur d'internalisation et une activité enzymatique lysosomale de remplacement sont décrits. Les complexes thérapeutiques multidomaines sont capables de pénétrer dans des cellules, de se séparer du lysosome, et de fournir l'activité enzymatique de remplacement au lysosome.The present invention provides compositions and methods for treating diseases characterized by enzyme deficiency. Multidomain therapeutic proteins containing an internalizing effector binding domain and replacement lysosomal enzymatic activity are disclosed. Multidomain therapeutic complexes are able to enter cells, separate from the lysosome, and provide replacement enzyme activity to the lysosome.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762516656P | 2017-06-07 | 2017-06-07 | |
| PCT/US2018/036306 WO2018226861A1 (en) | 2017-06-07 | 2018-06-06 | Compositions and methods for internalizing enzymes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA47657A1 true MA47657A1 (en) | 2021-06-30 |
| MA47657B2 MA47657B2 (en) | 2022-09-30 |
Family
ID=76635530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA47657A MA47657B2 (en) | 2017-06-07 | 2018-06-06 | Compositions and methods for internalizing enzymes |
Country Status (1)
| Country | Link |
|---|---|
| MA (1) | MA47657B2 (en) |
-
2018
- 2018-06-06 MA MA47657A patent/MA47657B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA47657B2 (en) | 2022-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019550261A1 (en) | Compositions and methods for internalizing enzymes | |
| NZ743008A (en) | Compositions and methods for internalizing enzymes | |
| SA520411662B1 (en) | Fusion proteins include enzymes for enzyme replacement therapy | |
| MA31862B1 (en) | Antiseptic antibodies and their uses | |
| MA45029A (en) | ANTI-PD-1 AND ANTI-LAG3 ANTIBODIES FOR CANCER TREATMENT | |
| MA52288B1 (en) | METHYL-MODIFYING ENZYME MODULATORS, COMPOSITIONS AND USES THEREOF | |
| MA49514B1 (en) | RECOMBINANT VIRAL PARTICLES WITH MODIFIED TROPISM, AND THEIR USES FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS | |
| MA29836B1 (en) | FUSION PROTEINS WITH ALBUMIN | |
| MY209496A (en) | Stable protein formulations | |
| MA33815B1 (en) | ANTAGONISTS, SPIRO-OXINDOLE TYPE, ONCOPROTEIN MDM2 | |
| UA109418C2 (en) | Zinc Finger Protein Designed for Plant Genes Involved in Fatty Acid Biosynthesis | |
| EA200901166A1 (en) | CONNECTIONS AND COMPOSITIONS AS GPR 119 ACTIVITY MODULATORS | |
| MA31999B1 (en) | Protein binding by antigen | |
| MA34559B1 (en) | FORMULATION FOR THE TREATMENT OF CANCER | |
| MA35873B1 (en) | Activin receptor polypeptide variants, alone or in combination with chemotherapy, and their uses | |
| MA35945B1 (en) | Inhibitors of beta-secretase | |
| EA200801164A2 (en) | PROTEIN INHIBITORS ACTIVATING 5-LIPOXYENASE (FLAP) | |
| WO2007089375A3 (en) | Compositions and methods for regulating complement system | |
| MA47392A1 (en) | Bis-octahydrophenanthrene carboxamides and their protein conjugates | |
| MX2014015551A (en) | Targeted iduronidase compounds. | |
| MA28779B1 (en) | VARIANTS OF APROTININE IMPROVED | |
| WO2020198662A8 (en) | Clec9a-based chimeric protein complexes | |
| MA47657A1 (en) | Compositions and methods for the internalization of enzymes | |
| JP2022078162A (en) | A pharmaceutical composition for the prevention or treatment of Alzheimer's disease, which comprises stem cells that secrete sRAGE. | |
| Lima et al. | Thymic alterations induced by Plasmodium berghei: expression of matrix metalloproteinases and their tissue inhibitors |